These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37267108)

  • 21. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
    Vuong HG; Ngo TNM; Dunn IF
    Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
    Saiji E; Pause FG; Lascombes P; Cerato Biderbost C; Marq NL; Berczy M; Merlini L; Rougemont AL
    Virchows Arch; 2019 Nov; 475(5):625-636. PubMed ID: 31240473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
    Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
    PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
    de Andrea CE; San-Julian M; Bovée JVMG
    Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of sarcomas by mutant IDH2.
    Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
    Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
    Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
    Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
    Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
    Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
    Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
    Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
    Trovarelli G; Sbaraglia M; Angelini A; Bellan E; Pala E; Belluzzi E; Pozzuoli A; Borga C; Dei Tos AP; Ruggieri P
    Clin Orthop Relat Res; 2024 Jan; 482(6):947-56. PubMed ID: 38170705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
    Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
    Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
    Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
    BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
    Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
    Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Status of IDH mutations in chondrosarcoma of the jaws.
    You Z; Zhang J; Zhang H; Li X; Sun Z; Sun L
    Int J Oral Maxillofac Surg; 2023 Jan; 52(1):26-31. PubMed ID: 35410781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
    Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
    Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Venneker S; Bovée JVMG
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic approaches in chondrosarcoma.
    Polychronidou G; Karavasilis V; Pollack SM; Huang PH; Lee A; Jones RL
    Future Oncol; 2017 Mar; 13(7):637-648. PubMed ID: 28133974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
    Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
    Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
    EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.